Business Context and Reporting Period
Atai Life Sciences N.V. (ATAI) filed this Form 8-K on November 4, 2025, to report the results of an extraordinary general meeting of shareholders held on the same date. The meeting addressed critical corporate actions including the proposed acquisition of Beckley Psytech Limited, a redomiciliation from the Netherlands to Delaware, and the appointment of new directors.
Key Financial Metrics
This filing is a current report regarding shareholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Shareholders approved all major proposals presented at the meeting. As of the record date (October 7, 2025), there were approximately 240,488,841 ordinary shares outstanding, with 156,318,136 shares present or represented at the meeting. The voting outcomes were as follows:
- Proposal 1 (Acquisition of Beckley Psytech): Approved with 121,090,088 votes For, 82,072 Against, and 282,047 Abstentions.
- Proposal 2 (Share Issuance for Acquisition): Approved with 120,951,244 votes For, 200,592 Against, and 302,371 Abstentions.
- Proposal 3A & 3B (Director Appointments): Approved the appointment of Mr. Cosmo Feilding-Mellen and Dr. Robert Hershberg as non-executive directors to serve until the 2028 annual general meeting.
- Proposal 4 (Name Change/Governing Documents): Approved with 155,434,494 votes For, 168,236 Against, and 715,406 Abstentions.
- Proposal 5 (LuxCo Merger): Approved the merger with atai Life Sciences Luxembourg S.A. with 119,295,309 votes For, 1,810,478 Against, and 348,420 Abstentions.
- Proposal 6 & 7 (Withdrawal Rights and Share Conversion): Approved amendments regarding cash compensation formulas and share class conversion for shareholders exercising withdrawal rights.
Guidance, Outlook, and Risks
Management indicated that the completion of the Redomiciliation and the Acquisition remains subject to certain closing conditions detailed in the Definitive Proxy Statement filed on September 24, 2025. The filing does not provide specific financial guidance or discuss new risks beyond the standard closing conditions associated with the merger and redomiciliation.
Investor Verification Checklist
- Verify the specific closing conditions for the Redomiciliation and Beckley Psytech acquisition in the Definitive Proxy Statement.
- Confirm the timeline for the name change and the operational impact of the Delaware redomiciliation.
- Review the terms of the Share Purchase Agreement dated June 2, 2025, regarding the Beckley Psytech acquisition.
- Monitor the status of the merger with atai Life Sciences Luxembourg S.A. and the treatment of withdrawal rights.